Red blood cell-platelet ratio and HR-restriction cube diagram during hospitalization. by Jie Zhao (49409)

Subjects:

Prognostic model for the red blood cell-platelet ratio and its trajectory categories during hospitalization. by Jie Zhao (49409)

Subjects:

Prognostic Impact of Red Blood Cell-Platelet Ratio Trajectory Categories after PSM. by Jie Zhao (49409)

Subjects:

Clinical baseline data. by Jie Zhao (49409)

Subjects:

Univariate analysis of ICU patients. by Jie Zhao (49409)

Subjects:

Prognostic model for the red blood cell-platelet ratio and its trajectory categories during ICU stay. by Jie Zhao (49409)

Subjects:

Impact of red blood cell-platelet ratio trajectories in the first four days before ICU admission on prognosis and clinical outcomes in the validation set. by Jie Zhao (49409)

Subjects:

Clinical baseline data after PSM. by Jie Zhao (49409)

Subjects:

Impact of red blood cell-platelet ratio trajectories on prognosis and clinical outcomes in the first four days before ICU admission in the training set. by Jie Zhao (49409)

Subjects:

International Classification of Diseases Codes. by Jie Zhao (49409)

Subjects:

Baseline data of clinical ICU patients. by Jie Zhao (49409)

Subjects:

S1 Data - by Hao Deng (409186)

Subjects:

Flowchart of the screening process. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the AMSTAR-2 assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Characteristics of included reviews. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the PRISMA assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

Result of the ROBIS assessments. by Huixia Ren (500186)

“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”

ROC curves for hub genes. by Jiyong Zhang (2498740)

Subjects:

Test soil parameters. by Yonggang Huang (223155)

Subjects:

Swelling pressure versus free swelling ratio curve. by Yonggang Huang (223155)

Subjects: